Nasopharyngeal Cancer Clinical Trial
Official title:
Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system cells (dendritic cell, DC). Dendritic cells are immune cells that help to stimulate our body's T lymphocytes to fight cancer by presenting specific proteins from the cancer cells. The investigators have developed in the laboratory a highly effective dendritic cell which is primed to activate T cells with the Epstein-Barr virus (EBV) proteins. It is hoped that this will stir an immune response to recognize NPC cells and kill them as part of body's immune surveillance system.
This study will involve two cohorts of patients, A and B. Patients are invited because they
have either (A) locally recurrent or metastatic nasopharyngeal cancer; or (B) stage 4 locally
advanced nasopharyngeal cancer (N2 or N3 disease and/or T4) and is known to be associated
with a high risk of distant relapse.
This study is carried out to find out the safety and recommended dose of CD137L-DC-EBV-VAX in
nasopharyngeal cancer. CD137L-DC-EBV-VAX is a product made from one of our own immune system
cells (dendritic cell, DC). Dendritic cells are immune cells that help to stimulate our
body's T lymphocytes to fight cancer by presenting specific proteins from the cancer cells.
The investigators have developed in the laboratory a highly effective dendritic cell which is
primed to activate T cells with the Epstein-Barr virus (EBV) proteins. It is hoped that this
will stir an immune response to recognize NPC cells and kill them as part of body's immune
surveillance system.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00370890 -
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
|
Phase 3 | |
| Recruiting |
NCT04340024 -
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
|
||
| Completed |
NCT00697619 -
To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT00078546 -
EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC)
|
Phase 1 | |
| Recruiting |
NCT04453826 -
Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
|
Phase 3 | |
| Active, not recruiting |
NCT01074021 -
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT03890185 -
Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC
|
Phase 2 | |
| Not yet recruiting |
NCT04158414 -
Applying PET/MR in Oncology - a Prospective Project
|
N/A | |
| Completed |
NCT02608073 -
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT03656250 -
Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
|
||
| Recruiting |
NCT02012699 -
Integrated Cancer Repository for Cancer Research
|
||
| Recruiting |
NCT04476641 -
A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors
|
Phase 2 | |
| Terminated |
NCT03144661 -
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06414577 -
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
|
Phase 2 | |
| Recruiting |
NCT03003182 -
A Study of Nasopharyngeal Carcinoma From Guangdong
|
N/A | |
| Not yet recruiting |
NCT06349889 -
Adebrelimab and Chemoradiotherapy in High-risk Locoregionally Advanced Nasopharyngeal Carcinoma
|
Phase 2 | |
| Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT05305131 -
Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
|
Phase 2 | |
| Completed |
NCT01800071 -
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
|
Phase 1 | |
| Recruiting |
NCT00304694 -
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
|
N/A |